USDL hit with shareholder lawsuit

Article

A controversy that U.S. Diagnostic had hoped to contain threatenedto mushroom into something larger this week after the imagingservices provider was hit with a shareholder lawsuit. The lawsuitcharges the West Palm Beach, FL, company with failing to

A controversy that U.S. Diagnostic had hoped to contain threatenedto mushroom into something larger this week after the imagingservices provider was hit with a shareholder lawsuit. The lawsuitcharges the West Palm Beach, FL, company with failing to revealthe background of Keith Greenberg, a mergers and acquisitionsconsultant who pleaded guilty to fraud charges in 1994.

The controversy began when investment house Bear, Stearns &Co. announced last month that it was discontinuing coverage ofUSDL due to the company's failure to disclose Greenberg's backgroundin public filings. USDL's stock dropped 22% after the revelation,although other investment houses continued to cover the stock.

USDL executives responded quickly to the imbroglio, acknowledgingGreenberg's past but pointing out that the convictions concerneda retail merchandising business he was involved with in the 1980s,long before USDL was founded. The company admitted, however, thatit incorrectly listed Greenberg as a co-founder and director ofmarketing, mergers, acquisitions, for USDL in a section of its1995 annual report. Greenberg actually works for his own firm,Coyote Consulting, and receives a finder's fee for each acquisitionthat passes muster with USDL's own due diligence.

The shareholder suit was filed Jan. 6 in U.S. District Court forthe Southern District of Florida, charging USDL with violatingthe Securities Exchange Act by failing to disclose Greenberg'sbackground. The lawsuit claims that USDL's stock was artificiallyinflated between March 1996 and Dec. 23, 1996, when Bear, Stearnsrevealed Greenberg's background.

USDL chairman and CEO Jeffrey Goffman said the claims in the lawsuitare "without merit" and that USDL will aggressivelydefend itself. Goffman pointed out that even with the recent drop,USDL's stock has almost doubled since January 1996, when it wastrading at about $5 a share.

"Our stock has had a temporary fluctuation," Goffmansaid. "Our company has outperformed expectations from inception."

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.